companies

Kayentis

Founded 2003
Employees 180+
Primary contact
19 bis
chemin du vieux Chêne
38240 Meylan
France
+33 4 76 00 54 20
Links
https://kayentis.com/
Sections
Kayentis is a global provider of eCOA (electronic Clinical Outcome Assessment) and Decentralized Clinical Trial solutions (DCTs). It helps pharma, biotech and CROs bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2003, Kayentis has been active in clinical development, with a strong specialization in eCOA solutions for phases II/III across a broad range of therapeutic areas. Over the years, it has developed a full range of services and has enlarged its portfolio beyond eCOA solutions to support the new normal of decentralized and hybrid trials. As of March 2023, the company has conducted digital data collection for over 280 clinical trials in 85 countries (18,000 sites and 98,000 patients), employing 120 languages. It has offices in the US (Boston), France (Grenoble) and Japan (Tokyo).
Select partners: ClinOne, OMRON Healthcare, OmniComm, SecureConsent, eNFORME.
Founded 2003
Employees 180+
Primary contact
19 bis
chemin du vieux Chêne
38240 Meylan
France
+33 4 76 00 54 20
Links
https://kayentis.com/
Sections

Funding 💰

Total $28.1M
Last round 🔗 $5M
Other
March 28, 2023.
Select investors XAnge, Seventure Partners, Extens, Bpifrance, Innovation Capital, LBO France

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Unified platform: Kayentis' Clin'form is a unique, fully integrated platform to collect and manage eCOA data in clinical trials. It offers complementary patient-centric features to support at home and on-site clinical trials. Clin'form can adapt and evolve according to trial specificities and integrates several services to guarantee trial efficiency as well as support patient engagement. It is also user-friendly, simplifying the patients, sites, and sponsors clinical trials experience. 🔗
  • Growing market: The eCOA market, which stood at $1.22 billion in 2021, is expected to grow to $4.08 billion by 2029, indicating a CAGR of 16.30% during the forecast period 2022 to 2029, according to Data Bridge Market Research. 🔗
  • Carbon-neutral clinical trials: Since 2016, Kayentis has calculated the carbon footprint of each of its 150 employees, enabling the company to closely monitor its carbon footprint and take pro-active steps to implement improvements year on year. Starting October 2020, it extended these initiatives to increase both Kayentis' carbon-neutrality and those of its pharma and biotech sponsors and Clinical Research Organization (CRO) customers, with a special focus on targeting carbon-neutrality within the eCOA phase of clinical trials. 🔗

Quotes 💬

“
We are delighted to support Kayentis' expansion in the US. Led by a strong management team, Kayentis has increased the number and size of its projects, with large pharma delivering an impressive growth track record in the last few years. By leveraging its latest Clin'Form platform and enhancing its commercial efforts on the ground, the company is in a particularly good position to accelerate its activities in the US market.
— Franck Noiret, managing director of LBO France 🔗
“
Kayentis has undergone a spectacular evolution since we first invested. Guillaume Juge and his management team have transformed the company into a renowned global player in digital clinical trials. Once again, we are fully confident in the team's aims for US market growth and in accelerating the development of its global clinical trial management solution for decentralized clinical trials.
— Cédric Berger, operating partner at Extens 🔗
“
We are proud to continue supporting Kayentis, a French and European leader in the fields of eCOA and DCT, and in accelerating its development, particularly in the US.
— Benoit Zilber, investment manager at Bpifrance 🔗
Last update: March 28, 2023